Diabetes Obes Metab 23(3):754762 Vilsbll T, Garber AJ (2012) Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
Contact a healthcare provider right away if you experience: Sudden, severe abdominal pain that doesnt improve or radiates to your back Persistent vomiting or inability to keep fluids down Swelling in the face, hands, or legs Yellowing of the skin or eyes (jaundice) Severe dizziness, fainting, or confusion Blood in your stool or black, tar-like stools Severe mood changes, including depression or anxiety Signs of an allergic reaction, such as trouble breathing or facial swelling If youre ever unsure whether a symptom is serious, err on the side of caution and call your healthcare provider
A lifter who wants the glucose and partitioning effects with minimal fat-loss pressure is reasoning from the bottom of this curve, far below the doses that drive the dramatic headline numbers
Like the gastric inhibitory peptide receptor (GIPR), GLP1R belongs to the B1 class of G protein-coupled receptors (GPCRs)
Theyre often described as overnight breakthroughs
Weeks 1-4 (2 mg dose) Weight loss is typically modest: 2-3% of body weight Appetite reduction may begin within the first week of injection Gastrointestinal side effects (nausea, decreased appetite) are most common during initial dosing For a person weighing 250 lbs (113 kg), this represents approximately 5-7 lbs (2-3 kg) Results may not be visually apparent to others at this stage Weeks 4-8 (4 mg dose) Weight loss accelerates as the dose increases Cumulative loss of approximately 4-5% of body weight Appetite suppression becomes more pronounced Clothing may begin to fit differently For a 250 lb individual: approximately 10-12 lbs (4-5 kg) lost Weeks 8-16 (6 mg to 9 mg) This is the period of most rapid dose escalation Cumulative loss of approximately 10-13% of body weight Results typically become noticeable to others Physical function improvements may become apparent (easier mobility, reduced joint discomfort) For a 250 lb individual: approximately 25-32 lbs (11-15 kg) lost Weeks 16-24 (reaching 12 mg maintenance) Full maintenance dose is reached around week 17 for the 12 mg regimen Weight loss rate is near its peak Cumulative loss of approximately 17-18% at 12 mg Significant changes in appearance, clothing size, and physical capabilities For a 250 lb individual: approximately 42-45 lbs (19-20 kg) lost Weeks 24-48 Weight loss continues at a gradually declining rate By week 48, mean loss of 24.2% at 12 mg (Phase 2 data) Cardiometabolic improvements (blood pressure, lipids, blood glucose) are well-established For a 250 lb individual: approximately 60 lbs (27 kg) lost Beyond 48 Weeks TRIUMPH-4 demonstrated continued weight loss to at least 68 weeks: -28.7% at 12 mg Whether weight loss continues beyond 68 weeks remains unknown
